Products › All Products
(2S, 6R)-6-amino-2-(2-thienyl)-1,4-thiazepine-5-one
- Information
ATP : Temocapril Intermediate
- CAS No.
110221-26-2
- Formula
C₉H₁₂N₂OS₂
- Mole Weight
228.33
Business Areas
Business Areas
Will become a leading company in the active pharmaceutical ingredient (API) industry.
Active Pharmaceutical Ingredients
We provide high-quality APIs that comply with global regulatory standards.
We stably supply high-purity active pharmaceutical ingredients (APIs) through strict GMP guidelines and systematic quality control systems.
All Products
Product list
68 products
- (2S, 6R)-6-amino-2-(2-thienyl)-1,4-thiazepine-5-one ATP : Temocapril Intermediate
- 3,4-DIHYDRO-6-HYDROXY-2(1H)-QUINOLINONE 6-HDC : Cilostazol Intermediate
- 5-(4-CHLOROBUTYL)-1-CYCLOHEXYL-1H-TETRAZOL CBT : Cilostazol Intermediate
- Oxiracetam Brain funtion enhancers
- Choline Alfoscerate (85%) Brain function enhancers
- (R)-Thioctic acid Tromethamine Diabetes treatments
- Acebrophylline Respiratory disease treatments
- Aceclofenac Anti-inflammatory / Analgesic drugs
- Acyclovir Antivirals
- Amlodipine Besylate High blood pressure treatments
- Amlodipine Maleate High blood pressure treatments
- Apixaban Antiplatelet drugs and anticoagulants
- Atorvastatin Calcium Trihydrate Anti-arteriosclerotic Drug
- Benfotiamine Vitamin
- Bepotastine besilate Itching (ocular pruritus), allergic conj
- Biphenyl Dimethyl Dicarboxylate Liver disease treatment
- Blonanserin Anti-depression/Anti-anxiety medicines
- Bosentan Hydrate High blood pressure treatments
- Bupropion HCl Anti-depression/Anti-anxiety medicines
- Carnitine Orotate Liver disease treatment
- Choline Alfoscerate (100%, powder) Brain function enhancers
- Cilnidipine High blood pressure treatments
- Cilostazol Anti-arteriosclerotic Drug
- Dapagliflozin citric acid Diabetes treatments
- Dapagliflozin Propanediol Monohydrate Diabetes treatments
- Dexibuprofen Anti-inflammatory / Analgesic drugs
- DL-Carnitine HCl Additives for preparation of medicines
- Duloxetine HCl Anti-depression/Anti-anxiety medicines
- Edoxaban tosylate monohydrate Antiplatelet drugs and anticoagulants
- Entecavir Liver disease treatment
- Erdosteine Respiratory disease treatments
- Esomeprazole Digestive problem medicines
- Etodolac Micronized Anti-inflammatory / Analgesic drugs
- Ezetimibe Anti-arteriosclerotic Drug
- Gliclazide Diabetes treatments
- Glimepiride Diabetes treatments
- Itopride HCl Digestive problem medicines
- L-Ornithine-L-aspartate anhydrous Liver disease treatment
- Levodropropizine Respiratory disease treatments
- Levosulpiride Digestive problem medicines
- Linagliptin Diabetes treatments
- Losartan Potassium High blood pressure treatments
- Loxoprofen Sodium Anti-inflammatory / Analgesic drugs
- Mirabegron Overactive bladder treaments
- Olmesartan Medoxomil High blood pressure treatments
- Omeprazole Digestive problem medicines
- Phendimetrazine Tartrate Anorexic
- Polaprezinc Digestive problem medicines
- Propiverine HCl Benign prostatic hyperplasia
- Pyridoxal Phosphate Hydrate Vitamin (enzyme co-factor)
- Rabeprazole Sodium Digestive problem medicines
- Raloxifene HCl Osteoporosis treatments
- Rebamipide Digestive problem medicines
- Rivaroxaban Micronized Antiplatelet drugs and anticoagulants
- Sarpogrelate HCl Antiplatelet drugs and anticoagulants
- Silodosin Benign prostatic hyperplasia
- Tamsulosin HCl Benign prostatic hyperplasia
- Tenofovir disoproxil fumarate Liver disease treatment
- Teprenone Digestive problem medicines
- Terazosin HCl Benign prostatic hyperplasia
- Tianeptine Sodium Anti-depression/Anti-anxiety medicines
- Ticagrelor Anti-arteriosclerotic Drug
- Tofisopam Anti-depression/Anti-anxiety medicines
- Triflusal Antiplatelet agent
- Valsartan High blood pressure treatments
- Varenicline Salicylate Smoking cessation aid
- Acetyl-L-Carnitine HCl Brain funtion enhancers
- Acid salt of 1-benzhydryl-3-azetidinyl amidinoacetate AZP-03 : Azelnidipine Intermediate
Hanseochem Co., Ltd. (hereinafter referred to as the 'Company') establishes and complies with the following Privacy Policy to protect and systematically manage the personal information of users in accordance with applicable personal data protection laws.
1. Purpose of Processing Personal Information
The Company processes personal information collected for the following purposes. Collected personal information will not be used for purposes other than the following:
- Product supply and customer inquiry/complaint handling
2. Items of Personal Information Processed
The Company processes the following personal information items:
- Customer Name
- Company Name / Department / Job Title
- Telephone Number / E-mail Address
3. Processing and Retention Period of Personal Information
The Company retains personal information within the retention period permitted by law or agreed upon at the time of collection. Records related to customer inquiries and disputes are retained for 5 years.
4. Destruction of Personal Information
In principle, the Company promptly destroys personal information once the purpose of collection and use has been achieved through secure electronic deletion or paper shredding methods.
5. Rights and Obligations of Data Subjects
Data subjects may exercise rights such as accessing, correcting, deleting, or requesting suspension of processing of their personal information in accordance with applicable laws.
6. Measures to Ensure the Security of Personal Information
The Company implements managerial and technical measures to secure personal information, including internal management plans, regular employee training, and access control.
7. Privacy Protection Officer
DepartmentManagement Department
OfficerYoung-Sung Yun
TitleGeneral Manager
Contact(Ext.) 106
8. Effective Date
This Privacy Policy is effective as of April 1, 2018.
We refuse the unauthorized collection of email addresses posted on this website using email collection programs or other technical devices. Please note that violations may result in criminal penalties under the Act on Promotion of Information and Communications Network Utilization and Information Protection, etc.
Date of Notice: January 1, 2026